Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 8/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25485151 | 0.89 | TP53 (0.37) | METTP53MEN1KMT2ATSHR | |
| SCHEMBL25484936 | 0.85 | MET (0.48) | METTP53TSHRHDAC1 | |
| SCHEMBL25489125 | 0.82 | TP53 (0.44) | METTP53MEN1KMT2AHDAC1 | |
| SCHEMBL25489127 | 0.76 | MET (0.41) | METTP53MEN1KMT2ATSHR | |
| SCHEMBL25489076 | 0.76 | L3MBTL1 (0.42) | METTP53MEN1KMT2ATSHR | |
| SCHEMBL30418953 | 0.74 | MET (0.41) | METTP53MEN1KMT2A | |
| SCHEMBL25416395 | 0.74 | MET (0.41) | METTP53MEN1KMT2A | |
| SCHEMBL31150642 | 0.74 | AKR1B1 (0.45) | METTP53MEN1KMT2ATSHR | |
| SCHEMBL25485108 | 0.74 | AKR1B1 (0.45) | METTP53MEN1KMT2ATSHR | |
| SCHEMBL24039001 | 0.73 | KDM4E (0.49) | TP53MEN1KMT2ATSHRHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336609-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-10-10 | — | — | US | disclosed |
| WO-2023091606-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336609-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | MET 4212/4885TP53 4800/4885MEN1 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.